ReviewCurrent diabetes reports2025
The Cardioprotective Effects of Adiponectin in Diabetes.
Review in Current diabetes reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Updated Understanding of Endocrine-Disrupting Substances Involved in the Obesity Epidemic and Their Associated Etiopathogenetic Mechanisms.Biomedicines · 2026Review
- Platelet Indices and Adipokines in Adults with Long-Standing Type 1 Diabetes.Journal of clinical medicine · 2026Article
- Exercise Intensity and Circulating Exerkine Responses: A Narrative Review of Selected Molecules.Biomolecules · 2026Review
- Circulating Adiponectin and Omentin Across Cardiometabolic Phenotypes: Links to Atherogenic Indices in Prediabetes and New-Onset Type 2 Diabetes.International journal of molecular sciences · 2026Article
- Reduced serum adiponectin and exercise predict depression in chronic heart failure patients and affect depressive-like behaviors in a mouse model.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAdiponectin, a hormone secreted by adipocytes, plays a crucial role in maintaining metabolic balance and supporting cardiovascular health. Although it is known for its protective effects, such as improving insulin sensitivity, reducing inflammation, and maintaining endothelial function, there are paradoxical associations between high adiponectin levels and increased cardiovascular mortality-referred to as the "adiponectin paradox"-which complicates its clinical interpretation. This review explores the cardioprotective effects of adiponectin in both type 1 and type 2 diabetes, focusing on its potential to regulate glucose metabolism and prevent cardiovascular complications. RECENT
findingsBy reviewing key studies, the article evaluates adiponectin's diverse roles and compares its effects on cardiovascular outcomes across diabetes subtypes, especially in diabetic cardiomyopathy, with an emphasis on congestive heart failure. The findings underscore the importance of further research into therapeutic strategies aimed at modulating adiponectin levels, particularly for individuals with diabetes and congestive heart failure. Understanding the dual nature of adiponectin's effects is critical for developing target interventions to improve cardiovascular outcomes in diabetic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.